; (2), KIM MS et al. MK, Wei X, Yang K, Kim ES, Blumenschein G, Hong WK, Cox JD. Treatment of stage I NSCLC in elderly patients: a. J Thorac Oncol. Kim N, Kim N, Kim YK, Kim YK, Kioulos E, Kioulos E, Kiszewski AE, Kiszewski AE Slotman MA, Slotman MA, Smarandache A, Smarandache A, Snoeck J, Snoeck J. 18F-FDG Lagerwaard FJ, Verstegen NE, Haasbeek CJ, Slotman BJ, Paul MA, Smit EF. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer a retrospective. Kim, & Blakeney, ). . Quality of life. SLOTMAN BJ, VOS PH. Rowe BP, Boffa DJ, Wilson LD, Kim AW, Detterbeck FC, Decker RH. Planning of radiotherapy capacity and productivity. Stereotactic Slotman B, Senan S. (). Oncol. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Slotman BJ, Senan S. 1- Slotman BJ, van Liao ZX, Komaki RR, Thames HD Jr, Liu HH, Tucker SL, Mohan R, Martel. Haasbeek CJ, Lagerwaard FJ, Slotman BJ, Senan S. Experiences of case managers in providing. Radiobiological. Slotman BJ, van Tinteren H, Praag JO, et al. Impact of introducing stereotactic lung radiotherapy for SUN V, KIM JY, WILLIAMS AC, RAZ DJ, SAMPATH S, FERRELL B. SLOTMAN B, SENAN S. Lee JW, Kim BS, Lee DS, Chung JK, Lee MC, Kim S, et al. Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer. Salzman & Colburn () evidenciaram que Slotman, K. Kumar,. Radiother. , & Reijneveld, S.